Display options
Cite
Ramos JA, Bianco FJ. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J Urol. 2012;28(1):9-14doi: 10.4103/0970-1591.94942.
Ramos, J. A., & Bianco, F. J. (2012). The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian journal of urology : IJU : journal of the Urological Society of India, 28(1), 9-14. https://doi.org/10.4103/0970-1591.94942
Ramos, Juan A, and Bianco, Fernando J. "The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications." Indian journal of urology : IJU : journal of the Urological Society of India vol. 28,1 (2012): 9-14. doi: https://doi.org/10.4103/0970-1591.94942
Ramos JA, Bianco FJ. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J Urol. 2012 Jan;28(1):9-14. doi: 10.4103/0970-1591.94942. PMID: 22557710; PMCID: PMC3339795.
Copy Download .nbib Format: NLM
Share it on

Indian J Urol. 2012 Jan;28(1):9-14. doi: 10.4103/0970-1591.94942.

The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

Indian journal of urology : IJU : journal of the Urological Society of India

Juan A Ramos, Fernando J Bianco

Affiliations

  1. Universidad de Carabobo, School of Health Sciences, Bárbula, Venezuela.

PMID: 22557710 PMCID: PMC3339795 DOI: 10.4103/0970-1591.94942

Abstract

Prostate cancer is a global public health problem, and it is the most common cancer in American men and the second cause for cancer-related death. Experimental evidence shows that prostate tissue possesses cannabinoid receptors and their stimulation results in anti-androgenic effects. To review currently relevant findings related to effects of cannabinoid receptors in prostate cancer. PubMed search utilizing the terms "cannabis," "cannabinoids," "prostate cancer," and "cancer pain management," giving preference to most recent publications was done. Articles identified were screened for their relevance to the field of prostate cancer and interest to both urologist and pain specialists. Prostate cancer cells possess increased expression of both cannabinoid 1 and 2 receptors, and stimulation of these results in decrease in cell viability, increased apoptosis, and decreased androgen receptor expression and prostate-specific antigen excretion. It would be of interest to conduct clinical studies utilizing cannabinoids for patients with metastatic prostate cancer, taking advantage not only of its beneficial effects on prostate cancer but also of their analgesic properties for bone metastatic cancer pain.

Keywords: Androgen antagonists; cannabinoids; cannabis; investigational therapies; prostatic neoplasms

References

  1. Pharmacol Ther. 2001 Apr;90(1):45-60 - PubMed
  2. Cancer. 2004 Jul 1;101(1):3-27 - PubMed
  3. Eur J Pharmacol. 1974 Apr;26(1):111-4 - PubMed
  4. Nature. 1993 Sep 2;365(6441):61-5 - PubMed
  5. N Engl J Med. 1974 Apr 18;290(16):872-4 - PubMed
  6. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  7. Clin Pharmacol Ther. 1975 Jul;18(1):84-9 - PubMed
  8. J Support Oncol. 2008 Mar;6(3):119-24 - PubMed
  9. J Clin Invest. 2003 Jan;111(1):43-50 - PubMed
  10. Curr Neuropharmacol. 2006 Jul;4(3):239-57 - PubMed
  11. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
  12. Neuroscience. 1999 Mar;90(3):923-31 - PubMed
  13. J Clin Invest. 2005 May;115(5):1298-305 - PubMed
  14. Cases J. 2009 May 18;2:7487 - PubMed
  15. Cancer. 2007 Nov 15;110(10):2119-52 - PubMed
  16. Brain Res. 2008 Jun 18;1215:69-75 - PubMed
  17. Curr Opin Support Palliat Care. 2009 Mar;3(1):7-13 - PubMed
  18. Eur J Cancer. 2009 Jan;45(1):174-82 - PubMed
  19. Pharmacol Ther. 1997;74(2):129-80 - PubMed
  20. Annu Rev Med. 2006;57:553-74 - PubMed
  21. Nature. 1993 May 20;363(6426):215 - PubMed
  22. Tetrahedron. 1965 May;21(5):1223-9 - PubMed
  23. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 - PubMed
  24. J Biol Chem. 2006 Dec 22;281(51):39480-91 - PubMed
  25. Eur J Pharmacol. 2004 Dec 15;506(2):179-88 - PubMed
  26. Mol Pharmacol. 1988 Nov;34(5):605-13 - PubMed
  27. J Neurosci. 1996 Oct 15;16(20):6601-11 - PubMed
  28. Eur J Biochem. 1995 Aug 15;232(1):54-61 - PubMed
  29. Arch Intern Med. 2007 Dec 10;167(22):2497-502 - PubMed
  30. Biochem Pharmacol. 1982 Feb 1;31(3):415-8 - PubMed
  31. Cancer. 2005 Jan 1;103(1):11-21 - PubMed
  32. Vitam Horm. 2001;62:199-230 - PubMed
  33. Nat Med. 2000 Mar;6(3):313-9 - PubMed
  34. Pharmacol Biochem Behav. 2008 Nov;91(1):38-46 - PubMed
  35. N Engl J Med. 1987 Oct 8;317(15):909-16 - PubMed
  36. Nat Neurosci. 2007 Jul;10(7):870-9 - PubMed
  37. Ann Intern Med. 1993 Nov 1;119(9):914-23 - PubMed
  38. CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21 - PubMed
  39. Pain Physician. 2007 May;10(3):399-424 - PubMed
  40. N Engl J Med. 2004 Oct 7;351(15):1502-12 - PubMed
  41. J Clin Invest. 2003 Aug;112(3):423-31 - PubMed
  42. Nat Rev Cancer. 2003 Oct;3(10):745-55 - PubMed
  43. Handb Exp Pharmacol. 2005;(168):509-54 - PubMed
  44. J Pain Symptom Manage. 2004 Jul;28(1):47-58 - PubMed
  45. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):101-21 - PubMed
  46. Cancer Res. 2005 Mar 1;65(5):1635-41 - PubMed
  47. Eur J Pharmacol. 2007 Mar 8;558(1-3):73-87 - PubMed
  48. J Clin Pharmacol. 1975 Feb-Mar;15(2-3):139-43 - PubMed
  49. Mol Cell Neurosci. 2000 Jun;15(6):510-21 - PubMed
  50. Handb Exp Pharmacol. 2007;(177):265-306 - PubMed
  51. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12198-203 - PubMed
  52. Cancer Res. 2001 Aug 1;61(15):5784-9 - PubMed
  53. Cancer Res. 1997 Feb 15;57(4):714-9 - PubMed
  54. FASEB J. 2001 Dec;15(14):2745-7 - PubMed
  55. Life Sci. 1985 Apr 22;36(16):1523-30 - PubMed
  56. Biochem Pharmacol. 1981 Feb 15;30(4):273-6 - PubMed
  57. Psychooncology. 2003 Mar;12(2):153-60 - PubMed
  58. Neuroscience. 1999;92(4):1171-5 - PubMed
  59. Life Sci. 1995;56(23-24):2111-8 - PubMed
  60. Nature. 1990 Aug 9;346(6284):561-4 - PubMed
  61. Pain. 2003 May;103(1-2):175-86 - PubMed

Publication Types